These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30122430)

  • 21. [Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma].
    Xue S; Yu T; Zhang Y; Shan L
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):656-60. PubMed ID: 26483340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
    Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
    Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib.
    Cha YJ; Cho BC; Kim HR; Lee HJ; Shim HS
    J Thorac Oncol; 2016 May; 11(5):e55-e58. PubMed ID: 26752677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
    Lee JK; Lee J; Kim S; Kim S; Youk J; Park S; An Y; Keam B; Kim DW; Heo DS; Kim YT; Kim JS; Kim SH; Lee JS; Lee SH; Park K; Ku JL; Jeon YK; Chung DH; Park PJ; Kim J; Kim TM; Ju YS
    J Clin Oncol; 2017 Sep; 35(26):3065-3074. PubMed ID: 28498782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
    Zhu YC; Du KQ; Wang WX; Song ZB; Xu CW; Chen G; Zhuang W; Lv TF; Song Y
    Lung Cancer; 2018 Jul; 121():101-104. PubMed ID: 29773459
    [No Abstract]   [Full Text] [Related]  

  • 28. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
    Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
    Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
    Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
    Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epidermal growth factor receptor (EGFR) mutation status before and after acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma].
    Ye SB; Li R; Shi SS
    Zhonghua Bing Li Xue Za Zhi; 2017 Feb; 46(2):98-101. PubMed ID: 28173668
    [No Abstract]   [Full Text] [Related]  

  • 32. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report of three EGFR TKI naïve lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology.
    Sakashita S; Shiba-Ishii A; Murata Y; Sekimoto R; Minami Y; Sato Y; Noguchi M
    Pathol Res Pract; 2018 Aug; 214(8):1224-1230. PubMed ID: 29887244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
    Suda K; Murakami I; Yu H; Kim J; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    J Thorac Oncol; 2017 Jun; 12(6):1015-1020. PubMed ID: 28193529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
    Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
    Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
    Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T
    J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
    Xu S; Liu X; Liu R; Shi T; Li X; Zhong D; Wang Y; Chen G; Chen J
    Thorac Cancer; 2017 Nov; 8(6):693-697. PubMed ID: 28786540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.
    Hashida S; Soh J; Toyooka S; Tanaka T; Furukawa M; Shien K; Yamamoto H; Asano H; Tsukuda K; Hagiwara K; Miyoshi S
    Oncol Rep; 2014 Jul; 32(1):145-52. PubMed ID: 24842519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
    Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.